Felice Verduyn-van Weegen
Director/Miembro de la Junta en Vico Therapeutics BV .
Origen de la red de primer grado Felice Verduyn-van Weegen.
| Entidad | Tipo de entidad | Industria | |
|---|---|---|---|
Columbia Business School
219
| College/University | Other Consumer Services | 219 |
Vrije Universiteit Amsterdam
35
| College/University | Other Consumer Services | 35 |
LSP Management Group BV
 LSP Management Group BV Investment ManagersFinance LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies.
30
| Subsidiary | Investment Managers | 30 |
EQT Life Sciences Group BV
 EQT Life Sciences Group BV Investment ManagersFinance EQT Life Sciences Group BV (EQT Life Sciences) is a venture capital firm, a subsidiary of EQT AB founded in 2022 after the acquisition of LSP by EQT. The firm is headquartered in Amsterdam, the Netherlands.
22
| Subsidiary | Investment Managers | 22 |
Vico Therapeutics BV
 Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022.
12
| Holding Company | Biotechnology | 12 |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands.
12
| Holding Company | Biotechnology | 12 |
Evommune, Inc.
 Evommune, Inc. Miscellaneous Commercial ServicesCommercial Services Evommune, Inc. engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pe?a, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Los Altos, CA.
10
| Holding Company | Miscellaneous Commercial Services | 10 |
Amolyt Pharma SAS
 Amolyt Pharma SAS Pharmaceuticals: MajorHealth Technology Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France.
8
| Holding Company | Pharmaceuticals: Major | 8 |
Egle Therapeutics SAS
 Egle Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Egle Therapeutics SAS is a biotech company based in Paris, France. Egle Therapeutics develops first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The French company leverages its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. The company was founded in 2020 by Luc Boblet, a serial biotech entrepreneur, and Dr. Eliane Piaggio, a renowned immunologist.
5
| Holding Company | Miscellaneous Commercial Services | 5 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Felice Verduyn-van Weegen a través de su red personal
| Empresa | Sector | Personas relacionadas | Puesto principal |
|---|---|---|---|
AM-Pharma Holding BV
 AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Chief Executive Officer Director/Board Member Chief Operating Officer Corporate Officer/Principal Corporate Officer/Principal | |
| DERMIRA, INC. | Pharmaceuticals: Major | Founder Director/Board Member Founder Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| University of Utrecht | College/University | Doctorate Degree Doctorate Degree Graduate Degree Graduate Degree Doctorate Degree | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
| University of Michigan | College/University | Undergraduate Degree Masters Business Admin Undergraduate Degree Undergraduate Degree | |
| University of Leiden | College/University | Undergraduate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
| Erasmus University Rotterdam | College/University | Graduate Degree Doctorate Degree Graduate Degree Doctorate Degree | |
LSP Advisory BV
 LSP Advisory BV Investment ManagersFinance Part of LSP Advisory Group BV, EQT Life Sciences is a healthcare investment firm based in Amsterdam, Netherlands. EQT Life Sciences has been connecting investors to inventors in the healthcare sector for over 30 years. The Dutch company has invested in close to two hundred private companies, raising billions of additional capital directed at supporting their R & D. EQT Life Sciences believes in fostering life and constant innovation in healthcare to achieve that goal. The company was founded in 1998, and Mark A. Wegter has been the CEO since then. Recently, EQT Life Sciences was acquired by EQT AB, one of the largest private equity firms in Europe, and among the top-ten private equity firms globally. | Investment Managers | Director/Board Member Chief Executive Officer Director/Board Member | |
| University of Amsterdam | College/University | Undergraduate Degree Doctorate Degree Graduate Degree | |
Intrexon ActoBiotics NV
 Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| The Trustees of Columbia University in The City of New York | College/University | Graduate Degree Graduate Degree Undergraduate Degree | |
| ALLERGAN, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Director of Finance/CFO Corporate Officer/Principal | |
Muna Therapeutics ApS
 Muna Therapeutics ApS Medical/Nursing ServicesHealth Services Muna Therapeutics ApS is a Danish private biopharmaceutical company that discovers and develops therapies to slow or stop neurodegenerative diseases such as Alzheimer's, frontotemporal dementia, and Parkinson's. Muna Therapeutics is based in Copenhagen, DK and was founded in 2020 by Simon Glerup and Bart de Strooper. The company focuses on identifying new medicines to preserve cognition and other brain functions and enhance resilience to these diseases. Rita Balice-Gordon has been the CEO of the company since 2020. | Medical/Nursing Services | Director/Board Member Chief Operating Officer Director/Board Member | |
| PHARVARIS N.V. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Founder | |
Imcheck Therapeutics SAS
 Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer | |
| Katholieke Universiteit Leuven | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
Andera Partners SCA
 Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
Artios Pharma Ltd.
 Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member | |
Arthur D. Little, Inc.
 Arthur D. Little, Inc. Miscellaneous Commercial ServicesCommercial Services Arthur D. Little, Inc. engages in the provision of management consulting services. It specializes in strategy and organization, operations management, technology and innovation management, corporate finance, and global carbon advisory serving corporations and organizations worldwide. The firm serves the automotive, healthcare, information, chemicals, consumer goods, retail, manufacturing, and transportation industries. The company was founded by Arthur Dehon Little and Roger Griffin in October 1886 and is headquartered in Boston, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
| Georgetown University | College/University | Undergraduate Degree Undergraduate Degree | |
Step Pharma SAS
 Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | Pharmaceuticals: Major | Chairman Chairman | |
Dynacure SA
 Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
Millendo Therapeutics US, Inc.
 Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics US, Inc. engages in the development of novel treatment for adrenal cancer. It focuses on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. The company was founded by Raili E. Kerppola, Julia C. Owens, and Gary D. Hammer in January 2012 and is headquartered in Ann Arbor, MI. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| New York University School of Medicine | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
Dr. Reddy's Research & Development BV
 Dr. Reddy's Research & Development BV Pharmaceuticals: MajorHealth Technology Dr. Reddy's Research & Development BV is engaged in the development and manufacture of injectable pharmaceutical products. It provides formulation, development, drug delivery, and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. The company was founded by Joost J. M. Holthuis on July 20, 1995 and is headquartered in Leiden, Netherlands. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| McGill University | College/University | Masters Business Admin Undergraduate Degree | |
Vyteris, Inc.
 Vyteris, Inc. Pharmaceuticals: MajorHealth Technology Vyteris, Inc. develops, manufactures and commercializes pharmaceutical products. It is engaged in the process of developing first active drug delivery patch to receive marketing clearance from the U.S. Food and Drug Administration. The drug delivery patch technology allows precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that may result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration. The company was founded on July 19, 2000 and is headquartered in Fair Lawn, NJ. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Neuravi Ltd.
 Neuravi Ltd. Medical SpecialtiesHealth Technology Neuravi Ltd. designs and develops medical devices for the treatment of acute stroke. Through its investment in the Neuravi Thromboembolic Initiative the company supports collaboration between engineers, clinicians and researchers to deepen the understanding of clot and occlusion dynamics to improve patient outcomes in stroke. Neuravi The company was founded by Mahmood K. Razav, Eamon Brady, John O'Shaughnessy and David Vale in 2009 and is headquartered in Galway, Ireland. | Medical Specialties | Director/Board Member Director/Board Member | |
QurAlis Corp.
 QurAlis Corp. Pharmaceuticals: MajorHealth Technology QurAlis Corp. engages in discovering and developing new therapies for amyotrophic lateral sclerosis and other neurological diseases. It offers therapeutic programs and targets, and biomarkers. The company was founded by Clifford Woolf, Kevin Eggan, Jonathan J. Fleming, and Kasper Roet and is headquartered in North Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
ReViral Ltd.
 ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member | |
ViCentra BV
 ViCentra BV Electronic Equipment/InstrumentsElectronic Technology ViCentra BV engages in the development of medical devices. It focuses in creating devices for diabetes patients. The company was founded by Tim Oakes and Joseph John Cefai in 2013 and is headquartered in Utrecht, the Netherlands. | Electronic Equipment/Instruments | Director/Board Member Director/Board Member | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Sanifit Therapeutics SA
 Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Biotechnology | Director/Board Member Director/Board Member | |
American Dermatological Association, Inc.
 American Dermatological Association, Inc. Miscellaneous Commercial ServicesCommercial Services American Dermatological Association, Inc. recognizes, discusses and develops solutions for problems in the area of dermatologic health care, research and education. The company was founded in 1876 and is headquartered in Fort Lauderdale, FL. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
| Aventis, Inc. | Corporate Officer/Principal Corporate Officer/Principal | ||
PamGene BV
 PamGene BV Pharmaceuticals: MajorHealth Technology PamGene BV provides biopharmaceutical products and clinical settings. It also provides PamChip biomarkers, such as tyrosine kinases, serine/threonine kinases, nuclear receptors, and reagent kits. The firm provides BioNavigator, a software tool for interpretation of PamChip measurements, as well as for performing data analysis for various PamChip experiments; and Evolve that enables data capture and analysis, as well as for the export of data into third party software formats. The company was founded by Tim Kievits in December 1999 and is headquartered in 's-Hertogenbosch, the Netherlands. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Health Economics Privak II NV
 Health Economics Privak II NV Finance/Rental/LeasingFinance Health Economics Privak II NV is a Belgian company that provides credit intermediation services. The private company is based in De Pinte, Belgium. The company was founded in 2017. | Finance/Rental/Leasing | Director/Board Member Director/Board Member | |
Peplin, Inc.
 Peplin, Inc. Pharmaceuticals: MajorHealth Technology Peplin, Inc. develops drugs and pharmaceutical products. The company was founded by James Harrison Aylward in 1998 and is headquartered in Emeryville, CA. | Pharmaceuticals: Major | President Corporate Officer/Principal | |
McKinsey & Co., Inc. (Belgium)
 McKinsey & Co., Inc. (Belgium) Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consultancy services. It serves businesses, governments, non governmental organizations, and non-profit organizations. The company was founded by James O. McKinsey in 1926 and is headquartered in Brussels, Belgium. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Calliditas Therapeutics Suisse SA
 Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member | |
Goldman Sachs & Co. LLC
 Goldman Sachs & Co. LLC Investment Banks/BrokersFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Investment Banks/Brokers | Corporate Officer/Principal Private Equity Analyst |
Estadísticas
Internacional
| Estados Unidos | 20 |
| Países Bajos | 14 |
| Bélgica | 5 |
| Francia | 5 |
| Reino Unido | 4 |
Sectorial
| Health Technology | 29 |
| Consumer Services | 12 |
| Finance | 5 |
| Commercial Services | 4 |
| Health Services | 3 |
Operativa
| Director/Board Member | 470 |
| Corporate Officer/Principal | 146 |
| Private Equity Investor | 102 |
| Independent Dir/Board Member | 74 |
| Undergraduate Degree | 64 |
Las relaciones más conectadas
| Insiders | |
|---|---|
| Amy Schulman | 45 |
| Pierre Legault | 45 |
| Raphaël Wisniewski | 45 |
| Eugene Bauer | 34 |
| Martijn Kleijwegt | 33 |
| René Kuijten | 30 |
| Rudy Dekeyser | 29 |
| Rémi Droller | 29 |
| Luc Dochez | 26 |
| John Paul de Koning | 21 |
| Robert Hopfner | 20 |
| David Cohen | 20 |
| Gilles Nobécourt | 19 |
| Thierry Laugel | 18 |
| Geert-Jan Mulder | 17 |
- Bolsa de valores
- Insiders
- Felice Verduyn-van Weegen
- Conexiones Empresas
